When you look at the semaglutide 5mg dosage chart or any injectable dosing reference, you cannot directly translate those numbers to sublingual equivalents
One tablespoon daily is a reasonable starting dose
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Save Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA)
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease 2025 [Press release]
The FDA generally allows compounding with these while they are under review
The blockbuster GLP-1 drugs have been battling it out in the highly lucrative obesity drug market, which is expected to hit $100 billion by 2030